Todays Report: Today, Analysts Set Lion Biotechnologies Inc. (LBIO) PT at $19.90

Today, Analysts Set Lion Biotechnologies Inc. (LBIO) PT at $19.90

Lion Biotechnologies Inc. (NASDAQ:LBIO) has received a consensus rating of “Buy” from the eight analysts that are currently covering the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $19.90.

A number of equities analysts have recently commented on the company. Zacks Investment Research downgraded Lion Biotechnologies from a “hold” rating to a “sell” rating in a report on Wednesday, November 9th. Jefferies Group restated a “buy” rating and issued a $13.00 price objective on shares of Lion Biotechnologies in a report on Monday, November 7th. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a report on Friday, November 4th. Roth Capital restated a “buy” rating and issued a $15.00 price objective on shares of Lion Biotechnologies in a report on Friday, August 26th. Finally, Chardan Capital set a $20.00 price objective on Lion Biotechnologies and gave the stock a “buy” rating in a report on Sunday, August 21st.

Several large investors have recently bought and sold shares of LBIO. FMR LLC raised its stake in shares of Lion Biotechnologies by 1.9% in the second quarter. FMR LLC now owns 5,645,114 shares of the biotechnology company’s stock worth $45,725,000 after buying an additional 102,886 shares during the period. Perceptive Advisors LLC raised its stake in shares of Lion Biotechnologies by 29.6% in the second quarter. Perceptive Advisors LLC now owns 3,611,976 shares of the biotechnology company’s stock worth $29,257,000 after buying an additional 824,720 shares during the period. Franklin Resources Inc. raised its stake in shares of Lion Biotechnologies by 55.6% in the second quarter. Franklin Resources Inc. now owns 3,388,500 shares of the biotechnology company’s stock worth $26,467,000 after buying an additional 1,210,500 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Lion Biotechnologies during the third quarter worth $19,234,000. Finally, BlackRock Fund Advisors raised its stake in shares of Lion Biotechnologies by 24.4% in the third quarter. BlackRock Fund Advisors now owns 2,248,479 shares of the biotechnology company’s stock worth $18,505,000 after buying an additional 441,276 shares during the period. Institutional investors and hedge funds own 79.02% of the company’s stock.

Lion Biotechnologies (NASDAQ:LBIO) opened at 7.30 on Tuesday. Lion Biotechnologies has a 1-year low of $4.24 and a 1-year high of $9.58. The stock’s market cap is $453.23 million. The company’s 50-day moving average price is $6.81 and its 200-day moving average price is $7.56.

Related posts

Leave a Comment